Esbriet (pirfenidone): Important safety update and new recommendations to prevent Drug-Induced Liver Injury (DILI)

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Active substance
Pirfenidone
Therapeutic area (MeSH)
Idiopathic Pulmonary Fibrosis
Procedure number
EMEA/H/C/002154/II/0066/G
Regulatory outcome
Variation
DHPC type
Type II variation
Human ATC code
L04AX05
Dissemination date
29/10/2020

How useful was this page?

Add your rating